The Food and Drug Administration (FDA) in the US approved primary human papillomavirus (HPV) testing for speculum-based cervical cancer screening ten years ago and, in May 2024, approved the self-collection technique. Our study defines the kappa agreement between self- and speculum-based collection techniques for 15 types of high-risk HPV. Additionally, we describe the sensitivity and specificity ratios for HPV testing using both collection methods. Participants recruited in 2020-2022 included 97 colposcopy attendees and 96 routine primary care screening attendees aged 30-65, who agreed to self-sample before their clinically scheduled speculum-based exam. Prevalence-based kappa calculated agreement, sensitivity and specificity ratios calculated accuracy using the cervical intraepithelial neoplasia grade 2 or worse (CIN 2+) threshold. The average ages were 45.9 (SD 10.5) and 46.2 (SD 11.0) years for the colposcopy and primary care attendees, respectively. HPV 16, 68, and 39 were the most common types detected. The lower bound of the 95 % Cl for kappa calculations was above 0.81, indicating almost perfect agreement across all HPV genotypes. The sensitivity and specificity ratios were consistent at 1.0 across both collection methods. The HPV positivity rate was significantly higher among colposcopy attendees at 66 % (64/97), compared to 14 % (13/96) among routine primary care screeners. The study identified 17 women with CIN2 + . Primary HPV screening with self-collection is equivalent to speculum-based collection among people aged 30-65. The findings emphasize the utility of self-collection in identifying high-grade lesions and the consistency of HPV detection across different collection methods.
Urine can provide a non-invasive screening method for high-risk human papillomavirus (hrHPV) infections. We aimed to compare detection rates of hrHPV and cervical intraepithelial neoplasia grade two or worse (CIN2+) using first-void urine (FVU) and clinician-collected cervical samples. We assessed whether the time of day of FVU collection impacts hrHPV detection. We recruited 188 participants, 30–65 years, before their colposcopy or routine screening from September 2020 through February 2022. Each collected FVU twice on the same day: at home and in the clinic before their appointments. We used prevalence-adjusted bias-adjusted kappa (PABAK) scores to compare hrHPV type-specific agreement, followed by McNemar's Exact test. We assessed both absolute and relative sensitivity and specificity to evaluate the accuracy of the collection techniques in predicting CIN2+ by hrHPV type. 95 hrHPV infections were detected in 70/188 (37.2 %) women. The PABAK agreement for hrHPV16 detection between FVU and the speculum was 0.95 (95 % CI: 0.91, 1.0). The agreement for hrHPV detection was almost perfect between home or clinic urine collection and the speculum specimen. The accuracy of CIN2+ detection measured by the sensitivity ratio of the clinic first-void specimen compared to the speculum specimen for hrHPV16 was 1.00 (0.62, 6.20). Most specificity ratios for all other hrHPV types were anchored at 1.0 with narrow confidence intervals. The time of day for FVU gave similar “any hrHPV” detection rates (27.5 % vs 32 %, p > 0.05). FVU hrHPV testing offers a potential cervical cancer screening alternative for women who cannot tolerate other collections.